Table 5. Outcomes of treatment.
Variable | Marfan syndrome | No Marfan syndrome | P value |
---|---|---|---|
Type A | |||
Death | |||
Medical | 5 (33.3%) | 219 (55.4%) | 0.091 |
Surgical | 19 (13.1%) | 575 (16.6%) | 0.265 |
Endovascular | 1 (50.0%) | 28 (38.9%) | 1.000 |
Hybrid | 0 (0.0%) | 8 (13.8%) | 1.000 |
Neurological complications | |||
Medical | 0 (0.0%) | 3 (7.7%) | 1.000 |
Surgical | 10 (8.2%) | 311 (10.5%) | 0.420 |
Endovascular | 0 (0.0%) | 12 (20%) | 1.000 |
Hybrid | 0 (0.0%) | 7 (13.2%) | 1.000 |
Type B | |||
Death | |||
Medical | 2 (4.3%) | 106 (7.8%) | 0.576 |
Surgical | 0 (0.0%) | 37 (17.6%) | 0.011 |
Endovascular | 1 (5.6%) | 61 (11.1%) | 0.708 |
Hybrid | 0 (0.0%) | 7 (14.3%) | 1.000 |
Neurological complications | |||
Medical | 0 (0.0%) | 0 (0.0%) | N/A |
Surgical | 2 (7.7%) | 24 (13.3%) | 0.542 |
Endovascular | 0 (0.0%) | 51 (10.3%) | 0.380 |
Hybrid | 0 (0.0%) | 4 (10.0%) | 1.000 |